Cavotricuspid isthmus ablation by means of very high power, short-duration, temperature-controlled lesions.


Journal

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 28 02 2022
accepted: 22 03 2022
pubmed: 6 4 2022
medline: 13 10 2022
entrez: 5 4 2022
Statut: ppublish

Résumé

A very high-power short-duration (vHPSD) strategy of radiofrequency (RF) ablation aims to minimize conductive heating and increase resistive heating. We evaluated the feasibility, efficacy and safety of the vHPSD ablation of the cavotricuspid isthmus (CTI) in patients presenting with typical atrial flutter (AFL). This prospective non-randomized study enrolled 28 consecutive patients (FAST Group) with typical AFL undergoing CTI ablation. The vHPSD ablation was performed applying 90 W, for 4 s, with an irrigation of 8 ml/min. Thirty consecutive patients who, previously, underwent CTI ablation by means of a contact force surrounding flow catheter guided by ablation index (500) served as control group (AI Group). In the FAST Group, the mean CTI length was 29 ± 6 mm, and the mean number of RF tags was 20 ± 9. The CTI bidirectional "first pass" block was reached in 25 (89%) patients. There were no major procedural complications. After a mean follow-up of 6 ± 2 months, one (3.5%) patient had arrhythmia recurrence. The vHPSD ablation was as effective as AI-guided ablation in achieving acute CTI block (rate of first pass 89% vs 93%, p = 0.59), with a shorter RF time (88 ± 40 s vs 492 ± 269 s, p < 0.001) and similar procedure (30 ± 4 min vs 34 ± 10 min, p = 0.5) and fluoroscopy time (103 ± 29 vs 108 ± 52 s, p = 0.7). At 8 months, the freedom from AFL recurrence was 96% in the FAST group and 97% in the AI group. Our preliminary data show that the vHPSD ablation represents an effective and safe ablation strategy to achieve bidirectional block for the treatment of typical AFL.

Sections du résumé

BACKGROUND BACKGROUND
A very high-power short-duration (vHPSD) strategy of radiofrequency (RF) ablation aims to minimize conductive heating and increase resistive heating. We evaluated the feasibility, efficacy and safety of the vHPSD ablation of the cavotricuspid isthmus (CTI) in patients presenting with typical atrial flutter (AFL).
METHODS METHODS
This prospective non-randomized study enrolled 28 consecutive patients (FAST Group) with typical AFL undergoing CTI ablation. The vHPSD ablation was performed applying 90 W, for 4 s, with an irrigation of 8 ml/min. Thirty consecutive patients who, previously, underwent CTI ablation by means of a contact force surrounding flow catheter guided by ablation index (500) served as control group (AI Group).
RESULTS RESULTS
In the FAST Group, the mean CTI length was 29 ± 6 mm, and the mean number of RF tags was 20 ± 9. The CTI bidirectional "first pass" block was reached in 25 (89%) patients. There were no major procedural complications. After a mean follow-up of 6 ± 2 months, one (3.5%) patient had arrhythmia recurrence. The vHPSD ablation was as effective as AI-guided ablation in achieving acute CTI block (rate of first pass 89% vs 93%, p = 0.59), with a shorter RF time (88 ± 40 s vs 492 ± 269 s, p < 0.001) and similar procedure (30 ± 4 min vs 34 ± 10 min, p = 0.5) and fluoroscopy time (103 ± 29 vs 108 ± 52 s, p = 0.7). At 8 months, the freedom from AFL recurrence was 96% in the FAST group and 97% in the AI group.
CONCLUSIONS CONCLUSIONS
Our preliminary data show that the vHPSD ablation represents an effective and safe ablation strategy to achieve bidirectional block for the treatment of typical AFL.

Identifiants

pubmed: 35378611
doi: 10.1007/s10840-022-01197-x
pii: 10.1007/s10840-022-01197-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

97-102

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Habibi M, Berger RD, Calkins H. Radiofrequency ablation: technological trends, challenges, and opportunities. Europace. 2021;23:511–9.
doi: 10.1093/europace/euaa328
Stabile G, Schillaci V, Strisciuglio T, Arestia A, Agresta A, Shopova G, De Simone A, Solimene F. In vivo biophysical characterization of very high power, short duration, temperature-controlled lesions. Pacing Clin Electrophysiol. 2021;44:1717–23.
doi: 10.1111/pace.14358
Leshem E, Zilberman I, Tschabrunn CM, Barkagan M, Contreras-Valdes FM, Govari A, Anter E. High-power and short-duration ablation for pulmonary vein isolation: biophysical characterization. JACC Clin Electrophysiol. 2018;4:467–79.
doi: 10.1016/j.jacep.2017.11.018
Barkagan M, Contreras-Valdes FM, Leshem E, Buxton AE, Nakaagawa H, Anter E. High-power and short-duration ablation for pulmonary vein isolation: safety, efficacy, and long-term durability. J Cardiovasc Electrophysiol. 2018;29:1287–96.
doi: 10.1111/jce.13651
Reddy VY, Grimaldi M, De Potter T, Vijgen MJ, Bulava A, Duytschaever MF, Martinek M, Natale A. Pulmonary vein isolation with very high power, short duration, temperature-controlled lesions: the QDOT-FAST Trial. JACC Clin Electrophysiol. 2019;5:778–86.
doi: 10.1016/j.jacep.2019.04.009
Richard Tilz R, Sano M, Vogler J, Fink T, Saraei R, Sciacca V, Kirstein B, Phan HL, Hatahet S, Delgado Lopez L, Traub A, Eitel C, Schlüter M, Kuck KH, Heeger CH. Very high-power short-duration temperature-controlled ablation versus conventional power-controlled ablation for pulmonary vein isolation: the fast and furious - AF study. Int J Cardiol Heart Vasc. 2021;35:100847.
pubmed: 34381869 pmcid: 8333145
Saoudi N, Cosio F, Waldo A, Chen SA, Iesaka Y, Lesh M, Saksena S, Salerno J, Schoels W. Classification of atrial flutter and regular atrial tachycardia according to electrophysiologic mechanism and anatomic bases: a statement from a joint expert group from the Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. J Cardiovasc Electrophysiol. 2001;12:852–66.
doi: 10.1046/j.1540-8167.2001.00852.x
Viola G, Stabile G, Bandino S, Rossi L, Marrazzo N, Pecora D, Bottoni N, Solimene F, Schillaci V, Scaglione M, Ocello S, Baiocchi C, Santoro A, Donzelli S, De Ruvo E, Lavalle C, Sanchez-Gomez JM, Pastor JFA, Grandio PC, Ferraris F, Castro A, Rebellato L, Marchese P, Adao L, Primo J, Barra S, Casu G. Safety, efficacy, and reproducibility of cavotricuspid isthmus ablation guided by the ablation index: acute results of the FLAI study. Europace. 2021;23:264–70.
doi: 10.1093/europace/euaa215
Harvey M, Kim YN, Sousa J, el-Atassi R, Morady F, Calkins H, Langberg JJ. Impedance monitoring during radiofrequency catheter ablation in humans. Pacing Clin Electrophysiol. 1992;15:22–7.
doi: 10.1111/j.1540-8159.1992.tb02897.x
De Bortoli A, Sun LZ, Solheim E, Hoff PI, Schuster P, Ohm OJ, Chen J. Ablation effect indicated by impedance fall is correlated with contact force level during ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2013;24:1210–5.
doi: 10.1111/jce.12215
Haines DE. The biophysics of radiofrequency catheter ablation in the heart: the importance of temperature monitoring. Pacing Clin Electrophysiol. 1993;16:586–91.
doi: 10.1111/j.1540-8159.1993.tb01630.x
Kwon HJ, Lee SS, Park YJ, Park SJ, Park KM, Kim JS, On YK. Effectiveness and safety of high-power and short-duration ablation for cavotricuspid isthmus ablation in atrial flutter. Pacing Clin Electrophysiol. 2020;43:941–6.
doi: 10.1111/pace.14019
Yavin HD, Leshem E, Shapira-Daniels A, Sroubek J, Barkagan M, Haffajee CI, Cooper JM, Anter E. Impact of high-power short-duration radiofrequency ablation on long-term lesion durability for atrial fibrillation ablation. JACC Clin Electrophysiol. 2020;6:973–85.
doi: 10.1016/j.jacep.2020.04.023
Golian M, Ramirez FD, Alqarawi W, Hansom SP, Nery PB, Redpath CJ, Nair GM, Shaw GC, Davis DR, Birnie DH, Sadek MM. High-power short-duration radiofrequency ablation of typical atrial flutter. Heart Rhythm. 2020;O2(1):317–23.
doi: 10.1016/j.hroo.2020.09.002
Kottmaier M, Deisenhofer I. Is ablation using high power short duration always suitable? Heart Rhythm O2. 2020;1(5):324–5.
doi: 10.1016/j.hroo.2020.11.003

Auteurs

Vincenzo Schillaci (V)

Clinica Montevergine, via Mario Malzoni, 5, 83013, Mercogliano, AV, Italy.

Teresa Strisciuglio (T)

Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Giuseppe Stabile (G)

Clinica Montevergine, via Mario Malzoni, 5, 83013, Mercogliano, AV, Italy. gmrstabile@tin.it.
Anthea Hospital, Bari, Italy. gmrstabile@tin.it.
Casa di Cura San Michele, Maddaloni, CE, Italy. gmrstabile@tin.it.

Armando Salito (A)

Clinica Montevergine, via Mario Malzoni, 5, 83013, Mercogliano, AV, Italy.

Alberto Arestia (A)

Clinica Montevergine, via Mario Malzoni, 5, 83013, Mercogliano, AV, Italy.

Alessia Agresta (A)

Clinica Montevergine, via Mario Malzoni, 5, 83013, Mercogliano, AV, Italy.

Gergana Shopova (G)

Clinica Montevergine, via Mario Malzoni, 5, 83013, Mercogliano, AV, Italy.

Antonio De Simone (A)

Anthea Hospital, Bari, Italy.

Francesco Solimene (F)

Clinica Montevergine, via Mario Malzoni, 5, 83013, Mercogliano, AV, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH